LabCorp

CND Life Sciences specializes in developing diagnostic tools for neurodegenerative diseases, particularly focusing on synucleinopathy. The company has introduced the Syn-One Test, which is designed to detect, visualize, and quantify abnormal phosphorylated alpha-synuclein in cutaneous nerve fibers. This commercially available test serves as an objective diagnostic aid for confirming synucleinopathy in patients suspected of having conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure. By providing a convenient and minimally invasive method for diagnosis, CND Life Sciences enhances the ability of medical professionals to accurately identify these complex disorders.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

BioReference Health - Laboratory Testing Businesses focused on oncology and oncology-related clinical testing services.

Percipio Health specializes in utilizing artificial intelligence to provide insights that assist clinicians and caregivers in maintaining a comprehensive understanding of a patient's health. The company has developed a platform that enhances the capabilities of computer vision software, allowing healthcare providers to accurately assess patient health status and identify medications. This technology empowers healthcare professionals to make informed decisions regarding patient care, ultimately improving health outcomes.

Teal Health is dedicated to improving women's health by providing at-home cervical cancer screenings. The company has developed an FDA-approved device that allows women to perform these essential screenings in the comfort and privacy of their own homes. By simplifying the process, Teal Health aims to encourage timely screenings, which are crucial for early detection and treatment, ultimately striving to eradicate cervical cancer in the United States. The initiative is supported by a group of committed investors who share the vision of transforming women's health experiences.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Praia Health is a cutting-edge consumer platform for health systems that transforms the delivery of personalised health solutions on a large scale, allowing digital transformation.

GLX Analytix is a biotechnology company focused on advancing personalized medicine through a proprietary class of blood biomarkers combined with artificial intelligence. The company specializes in early diagnosis and monitoring of chronic diseases, providing clinicians with tools to track disease progression, monitor treatment responses, and predict flare-ups. By enhancing patient empowerment and enabling self-monitoring, GLX Analytix aims to optimize treatment plans and improve health outcomes. The company collaborates with institutions like Harvard Medical / Wyss Diagnostic Accelerator and has received recognition for its innovative approach, highlighting its potential to significantly impact patient lives globally.

PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Acclinate is a venture-backed company focused on enhancing representation and diversity in genomic research and clinical trials through its digital health platform. By utilizing machine learning and predictive analytics, Acclinate automates the processes of identifying, educating, engaging, and retaining diverse participants for research studies. This approach not only empowers communities to improve their health outcomes but also helps biopharmaceutical organizations reduce the overall costs associated with drug development. Through sustained engagement and AI-driven insights, Acclinate aims to foster better health practices and outcomes within underrepresented populations.

Phenomix Sciences is a biotechnology company that specializes in biotech, life science, metabolomics, and genomics. It provides healthcare solutions that will enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. The company was founded in 2017 and headquartered in New York, United States.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Xcell Biosciences, Inc. is a San Francisco-based life science start-up founded in 2012, focused on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a bench-top primary cell control system that captures, grows, and analyzes cancer cells directly from patient blood samples. Their proprietary technology allows for precise control of primary cell phenotype and function, enhancing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences provides researchers with advanced tools for cell maintenance and expansion, ultimately aiming to improve therapy development and clinical outcomes.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

HealthEC, LLC specializes in developing technology solutions for the exchange of healthcare information and management of population health, both in the United States and internationally. The company offers a comprehensive Population Health Management platform that consolidates various elements of care management, including patient attribution, care coordination, and analytics, to serve payers, providers, and employers. Key offerings include "ACO in a Box," which integrates population management and patient engagement functionalities; transformation consulting services; and a Physician Quality Reporting System designed to incentivize quality information reporting. Additionally, HealthEC provides solutions for provider management, claims processing, and extensive analytics to monitor performance and risk. The company, originally founded as IGI Health in 1997, rebranded to HealthEC in 2013 and is headquartered in Edison, New Jersey, with operations extending to Indiana and India. Its client base encompasses hospitals, health systems, physician practices, health plans, and self-insured employers.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Baystate Health is an integrated healthcare delivery system that serves nearly one million residents in western Massachusetts. It comprises multiple hospitals and ancillary services, aiming to provide comprehensive medical care to the community. In addition to its healthcare services, the Baystate Health Foundation, established in 2000 and based in Springfield, supports the organization through philanthropic efforts. This independent non-profit foundation focuses on fundraising for healthcare-related activities, benefiting Baystate Health and its subsidiaries, which are designated as tax-exempt, not-for-profit entities. The foundation manages its investments through its executive management team, ensuring that charitable donations and endowments effectively support the healthcare needs of the community.

Evvy is a company focused on improving female health by offering at-home vaginal microbiome tests. These tests utilize metagenomic sequencing to analyze symptoms and identify risks associated with important health issues. By providing personalized reports, Evvy aims to empower women with insights about their bodies, thereby addressing the gender health gap and enhancing overall health outcomes for women.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that connect diagnosis and treatment through a comprehensive ecosystem of devices, software, and services. By empowering patients to monitor their health and manage diseases, Vital Bio aims to enhance the overall healthcare experience. Their approach seeks to reduce disparities in healthcare outcomes and redistribute control to patients while equipping healthcare providers with the tools necessary to achieve better results.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.

Clinical Outreach Laboratory Services provides all medical and clinical trials.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

Getlabs, Inc. is a digital health platform based in Santa Monica, California, that specializes in at-home diagnostics. Founded in 2018, the company facilitates the scheduling of home lab appointments, where mobile phlebotomists visit patients to collect blood samples and other diagnostic tests. These samples are then delivered to laboratories for processing, allowing healthcare organizations to enhance patient care and adherence by providing same-day, nationwide service. Getlabs aims to bridge the gap between virtual and in-person healthcare, thereby improving access to essential diagnostic services. The company has secured $50 million in funding from strategic investors, including major diagnostic laboratories.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

PetDx is a San Diego-based molecular diagnostics company focused on enhancing pet health through advanced genomic technologies. The company's primary offering, OncoK9, is a pioneering multi-cancer early detection test that allows veterinarians to identify cancer in dogs through a simple blood draw. This first-in-class liquid biopsy utilizes next-generation sequencing and proprietary bioinformatics to analyze genetic material, facilitating early detection, characterization, and management of cancer in pets. By providing a non-invasive testing option, PetDx supports veterinarians in delivering improved care and outcomes for canine patients.

Toxikon Corp., founded in 1977 and re-established in 1982 by Dr. Laxman Desai, specializes in preclinical contract research services for the pharmaceutical, biotechnology, and medical device industries. With a strong foundation in life sciences, Toxikon has been advancing innovations for over 30 years, providing a range of testing services that support the development of new therapies. The company offers in vivo, in vitro, and analytical testing to facilitate the transition of therapies from concept through research, trials, and commercialization. Toxikon's facilities, including an 80,000-square-foot main location in Bedford, MA, and an adjacent 45,000-square-foot laboratory space, enable it to conduct comprehensive studies, including toxicology and bioanalytical support services. Through its expertise and extensive capabilities, Toxikon helps clients achieve regulatory approvals and effectively bring their products to market.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Xcell Biosciences, Inc. is a San Francisco-based life science start-up founded in 2012, focused on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a bench-top primary cell control system that captures, grows, and analyzes cancer cells directly from patient blood samples. Their proprietary technology allows for precise control of primary cell phenotype and function, enhancing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences provides researchers with advanced tools for cell maintenance and expansion, ultimately aiming to improve therapy development and clinical outcomes.

Ovia Health is a digital healthcare company that provides a comprehensive maternity and family benefits solution aimed at supporting women and families throughout the parenthood journey. Formerly known as Ovuline, the company offers a suite of mobile applications, including Ovia Fertility and Ovia Pregnancy, which deliver personalized information and resources related to fertility, pregnancy, and parenting. By empowering women with customized health insights, Ovia Health enables them to take control of their reproductive health and start families with confidence, ultimately transforming healthcare into a lifestyle choice.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

Biospectal is a company focused on remote patient monitoring and biosensing, having developed the OptiBP smartphone app and data platform for blood pressure measurement. This innovative app allows users to measure their blood pressure using the built-in camera of a smartphone, capturing blood flow through the fingertip in a quick and easy manner. The measurement process takes approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal’s proprietary algorithms analyze the optical signals captured by the camera to provide accurate blood pressure readings. Currently, the public beta of the OptiBP app for Android is available in several countries, including the United States, the United Kingdom, France, Germany, Spain, and Switzerland. This technology empowers individuals to monitor their blood pressure anytime and anywhere, transforming smartphones into medical-grade devices without the need for additional peripherals.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms

TrakCel Ltd. is a technology company that provides a comprehensive suite of integrated solutions for managing the cell therapy supply chain, catering to both autologous and allogeneic therapies. Founded in 2012 and headquartered in Cardiff, United Kingdom, TrakCel offers a cloud-based Cell Orchestration Platform that enhances the efficiency of cell and gene therapy development. This platform enables users to collate, track, and document critical information throughout various stages of therapy programs, facilitating compliance with regulatory audits. The company serves a diverse clientele, including medical centers, logistics providers, manufacturers, and therapy developers, and collaborates with both commercial and academic organizations focused on improving human health. By replacing outdated paper-based systems, TrakCel's technology helps streamline data management, reporting, and analysis needs in clinical trials, ultimately reducing time, costs, and risks associated with therapy development.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Navigating Cancer, Inc. offers a web-based patient care and engagement portal specifically designed for cancer patients and their healthcare teams. Founded in 2008 and based in Seattle, Washington, the platform enables cancer survivors to manage and organize their medical information, track their health, and stay informed about their treatments. It serves as a resource for patients to access articles on various types of cancer and chemotherapy, facilitating discussions about their conditions with peers and healthcare professionals. The portal aims to enhance patient-centered care by connecting patients with their healthcare teams, streamlining practice workflows, and ultimately improving the quality of oncology care while reducing costs.

Weavr Health is transforming blood collection by enabling patients to collect clinical-grade blood samples in their own homes without the need for a phlebotomist. The company has developed a self-collection device that allows average users to perform complex sample processing steps without requiring trained professionals or specialized laboratory equipment. This innovation simplifies the diagnostic testing process, making it more efficient and accessible at the point of care. By focusing on user-friendly solutions, Weavr Health aims to enhance the healthcare experience and streamline blood collection procedures.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, founded in 2012. The company specializes in developing medical products and research tools focused on male fertility management. Its notable offerings include the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a remote blood sampling device for diagnostic testing. Sandstone also manufactures the Trak fertility system, which consists of an engine, a disposable test plate, a sample collection cup, and a dropper, allowing men to monitor their sperm quality and enhance their fertility potential. Additionally, the company provides a mobile application that allows users to track fertility statistics over time, identify potential fertility issues, and take proactive steps to improve their reproductive health. Through these innovations, Sandstone Diagnostics aims to empower individuals to manage their fertility from the comfort of their own homes.

Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

The Recovery Platform is a specialized medical enterprise designed to support physicians and patients in the practice of medication-assisted treatment (MAT) for substance use disorders. This platform provides essential tools that enable healthcare providers to monitor patient compliance and track progress effectively. It also facilitates telehealth communication and schedule management, thereby streamlining the treatment process. By assisting physicians in managing compliance requirements, the Recovery Platform promotes best practices in transitioning patients from opioid dependence to recovery. Through its comprehensive features, the platform aims to enhance the overall effectiveness of MAT, ensuring that both patients and providers can navigate the complexities of treatment with greater ease and success.

Chiltern International Limited is a prominent contract research organization that specializes in clinical development and scientific services for the pharmaceutical and biotechnology sectors. The company offers a comprehensive range of services, including early and late-phase clinical development, biostatistics, and medical and regulatory affairs. Chiltern serves various specialty areas within the biopharmaceutical and medical device industries, utilizing diverse engagement models to meet the specific needs of its clients. In addition to its clinical services, Chiltern also provides resourcing solutions to support the operational requirements of its partners. Through its expertise and collaborative technologies, the company plays a crucial role in advancing clinical research and development.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. The company provides a range of diagnostic services, including cytology and pathology, to healthcare providers and their patients across the United States. Its offerings include testing for human papillomavirus (HPV) using the Digene Hybrid Capture 2 method, as well as tests for gonorrhea and chlamydia. Additionally, ClearPath provides supplemental tissue diagnostics, such as immunohistochemistry and frozen section analysis. The company also specializes in triple testing to identify common vaginitis pathogens and offers Vysis UroVysion testing for non-invasive assessment of bladder cancer. ClearPath Diagnostics analyzes cells from various organs, including breast and thyroid fine needle aspirations and urine specimens. Founded in 1975, it has been operating as a subsidiary of Laboratory Corp. of America Holdings since October 2016.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Calif.-based laboratory firm

Safe Food International (SFI) is an organization based in Washington, D.C., dedicated to enhancing global food safety through the collaborative efforts of consumer organizations. It aims to address common food safety issues by facilitating the development and implementation of national food safety programs. SFI works to ensure that these programs effectively approve food products prior to consumption or export, while also promoting measures to prevent intentional contamination of food supplies. Through awareness programs and strategic initiatives, SFI strives to create a safer food environment for consumers worldwide.

Ativa Medical Corporation is a medical device manufacturing company focused on developing and commercializing point of care testing diagnostic products tailored for decentralized healthcare settings. Founded in 2008 and headquartered in Saint Paul, Minnesota, the company specializes in providing analyzers that conduct essential hematology and clinical chemistry tests, along with disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. Ativa Medical aims to deliver diagnostic test results in moments rather than hours or days, serving a diverse range of clients, including hospital departments, physician's offices, and remote healthcare clinics across the globe.

Bode Technology Group, Inc. specializes in human DNA analysis and innovative collection products primarily for law enforcement and identification markets. The company offers a comprehensive range of services, including high-throughput DNA testing, casework analysis, missing person identification, and databanking of convicted offenders and arrestees. Bode's patented DNA collection systems are utilized globally for gathering DNA from various sources, including crime scenes and familial relationships for genealogy purposes. Their teams of analysts and researchers continuously explore advanced methodologies and technologies to enhance the analysis of challenging samples, such as bones and aged tissue. Additionally, Bode provides customized consulting, training, and validation services, reinforcing its commitment to supporting law enforcement agencies and state governments in their forensic endeavors.

Vivify Health Inc. operates a cloud-based, device-agnostic software platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This platform aims to reduce hospital readmissions and associated healthcare costs by enabling virtual interactions between patients and doctors. Vivify Health offers various personal health devices, including tablets, weight scales, and pulse oximeters, to support its remote care management solutions. Founded in 2009 and based in Plano, Texas, the company was formerly known as Intuitive Health, Inc. and rebranded in May 2013. Vivify Health operates as a subsidiary of Optum, Inc., following a transaction announced in December 2019. Through its technology, the company seeks to enhance population health, optimize patient engagement, and improve overall patient satisfaction while facilitating the expansion of physician practice services.

Covance Inc. is a leading provider of contract research services focused on the pharmaceutical, biotechnology, and medical device industries. Established in 1987 and headquartered in Princeton, New Jersey, the company offers a comprehensive suite of early- and late-stage development services, including preclinical and clinical pharmacology, biomarker services, and full management of Phase II and III clinical studies. Additionally, Covance provides laboratory testing services to the chemical, agrochemical, and food industries, positioning itself as a market leader in toxicology, central laboratory services, and clinical trial management. The company is known for its extensive experience and specialized expertise, having contributed to the development of the top 50 prescription drugs available today. As part of Laboratory Corporation of America Holdings, Covance is dedicated to advancing healthcare by helping clients reduce the time and costs associated with drug development through high-quality nonclinical, clinical, and commercialization services.

LipoScience, based in Raleigh, North Carolina, specializes in developing in vitro diagnostic tests utilizing nuclear magnetic resonance (NMR) technology. The company's flagship product, the NMR LipoProfile test, quantifies low density lipoprotein particles (LDL-P) in blood samples, offering crucial insights for physicians and patients to tailor heart disease risk management. With more than 8 million tests ordered, LipoScience is at the forefront of personalized diagnostics, providing actionable data that enhances patient care and treatment strategies.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Stateless Networks Inc. is a company that specializes in performance infrastructure and networking solutions tailored for enterprises, service providers, and the federal government. Founded in 2012 and headquartered in San Francisco, California, Stateless offers the Stateless AutoWare SDN Fabric Manager, a software application designed to enhance network monitoring and management. This tool facilitates quicker deployments, boosts resilience, automates administrative tasks, and enables swift recovery from service disruptions. The company focuses on transforming network operations through a combination of deep network insights and advanced distributed systems, catering specifically to enterprise data centers. Stateless collaborates with leading network and infrastructure vendors to provide solutions to major private data center operators, emphasizing the integration of physical and virtual networking layers.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

MEDTOX Scientific operates a certified drug testing and clinical laboratory that provides a range of forensic and clinical laboratory services. Catering to physician offices, corporations, clinics, health organizations, and government agencies, the company specializes in medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. The laboratory is committed to delivering efficient and effective testing programs while prioritizing excellent customer service and strong client relationships. With a focus on responsiveness and adaptability, MEDTOX ensures that it meets the diverse needs of its clients.

Clearstone Central Laboratories is the largest and most experienced private company.

Orchid Cellmark Ltd. provides genotyping and DNA testing services for forensic, human identity testing, and agricultural applications.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. provides a range of laboratory testing solutions, specializing in anatomic and molecular pathology services. The company offers diagnostic cytopathology and histopathology, as well as immunohistochemistry services that include a variety of antibodies for biomarker analysis and customized methodologies for processing biopsy specimens. DCL Medical Laboratories also supports clinical trials and delivers reference testing focused on women's health, including ThinPrep Pap test processing, HPV molecular testing, and screening for chlamydia, gonorrhea, and cystic fibrosis carriers. Serving the medical industry across the United States, DCL Medical Laboratories aims to enhance diagnostic accuracy and patient care through its comprehensive testing services.

Monogram Biosciences is a leading developer of innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company specializes in molecular diagnostics and offers products such as Trofile, an assay that determines the tropism of a patient's HIV, facilitating personalized treatment options. Additionally, Monogram provides VeraTag technology, which enhances the development of targeted therapeutics. The company's solutions cater to healthcare providers and pharmaceutical companies, contributing to advancements in precision medicine and improving patient outcomes.

Tandem Labs is a bioanalytical contract research organization based in Salt Lake City, Utah, that supports pharmaceutical and biotechnology companies in their clinical and preclinical drug development programs. Founded in 1995, Tandem Labs specializes in mass spectrometry and immunochemistry services, offering a range of bioanalytical studies. The company develops, validates, and performs spectrometry-based methods in compliance with Good Laboratory Practice (GLP) standards, providing services such as method development and validation, dose formulation analysis, and clinical sample analysis. Additionally, Tandem Labs delivers immunoanalytical services and biomarker services, catering to both GLP and non-GLP discovery needs. The organization was acquired by LabCorp in January 2008, further enhancing its capabilities in drug development support.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Litholink Corp is a clinical laboratory based in Chicago, Illinois, specializing in kidney disease management. The company offers 24-hour urine testing services aimed at kidney stone prevention, providing accurate test results and personalized treatment recommendations for patients. Litholink's national infrastructure supports seamless integration of its services, ensuring high levels of customer support and convenience for clients managing their laboratory needs.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and customer support. The company provides a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to standard laboratory testing, Esoterix offers services tailored for physician specialists and clinical trials. The company also supports its operations with ancillary services, including information technology, managed care, and billing solutions, ensuring a comprehensive approach to laboratory testing and customer service.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Pathology offers a broad array of testing procedures, combining the expertise of an academic-based center with the personal service of a local pathologist. Their services include dermatopathology, gastrointestinal pathology, and uropathology.

Dynacare is an independent clinical laboratory that provides a range of testing services to the healthcare sector in select regions of the United States and Canada. The company operates 26 central laboratories, including two that focus on esoteric testing, along with 115 rapid response labs and 302 patient service centers across 21 states and two Canadian provinces. Dynacare specializes in the clinical laboratory testing of body fluids, tissues, and other specimens, including human cells and molecular diagnostics. By offering diverse diagnostic lab services, the company aims to meet the needs of its clients with competitive pricing.

Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity.

ViroMed Laboratories is an FDA-registered laboratory that specializes in infectious disease testing. As a member of LabCorp's Specialty Testing Group, the laboratory provides a range of testing services tailored to support human cells, tissues, and cellular and tissue-based product (HCT/P) donor clients. Its offerings include reproductive donor testing, tissue and eye bank testing, bone marrow and stem cell testing, cord blood testing, and blood testing. ViroMed serves various sectors, including biotechnology, pharmaceuticals, chemicals, medical devices, and integrated healthcare, ensuring that its clients meet regulatory and safety standards in their respective fields.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.